TradeFlare's AI research teams analysed AMLX on 19 market nights between May 4, 2026 and October 1, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| October 1, 2026 | HOLD | $29.10 | $33.47 / $24.74 | -3.1% | not yet | The stock is at a critical juncture with conflicting team signals, requiring observation of price action near key levels. |
| September 30, 2026 | HOLD | $29.28 | — / — | -5.7% | not yet | The current setup does not warrant a BUY, and a HOLD is appropriate given the conflicting signals. |
| September 29, 2026 | HOLD | $29.85 | — / — | -4.2% | not yet | The current market and stock setup does not warrant a buy. |
| September 28, 2026 | HOLD | $29.49 | — / — | -6.9% | not yet | The current setup does not warrant a buy, and a HOLD is appropriate until a clearer signal emerges. |
| September 25, 2026 | HOLD | $30.14 | $34.66 / $25.62 | -5.8% | not yet | The current setup is not compelling enough for an immediate entry given the conflicting technical signals and high risk. |
| September 24, 2026 | HOLD | $30.60 | — / — | -6.8% | not yet | The current setup does not warrant a buy, and the market regime is neutral, suggesting a cautious approach. |
| September 14, 2026 | HOLD | $31.62 | $32.69 / $24.34 | -3.7% | -18.3% | Awaiting price stabilization and a constructive base near key support before reassessing risk-reward. |
| August 25, 2026 | BUY | $38.15 | $47.69 / $32.43 | -9.7% | -18.3% | The post-earnings drift suggests continued upward momentum over the coming weeks. |
| August 24, 2026 | BUY | $38.66 | $57.99 / $29.00 | -11.5% | -13.5% | The post-earnings drift signal suggests momentum could persist for several weeks. |
| August 22, 2026 | BUY | $38.66 | $48.33 / $32.86 | -11.5% | -13.5% | The post-earnings drift signal suggests momentum could persist for several weeks. |
| August 21, 2026 | BUY | $39.66 | $47.59 / $33.71 | -10.1% | -16.2% | The post-earnings drift suggests momentum could persist for a few weeks. |
| August 5, 2026 | BUY | $21.87 | — / — | +6.9% | +57.9% | The current setup does not meet the minimum R/R requirements for a trade. |
| July 31, 2026 | BUY | $20.75 | $24.89 / $17.64 | +12.4% | +71.0% | The stock is near its 52-week high and the technicals suggest momentum continuation. |
| July 29, 2026 | BUY | $19.55 | — / — | +10.8% | +87.9% | The current setup does not meet the minimum requirements for a trade. |
| July 28, 2026 | BUY | $19.49 | — / — | +11.9% | +91.6% | The stock is near a 52-week high but exhibits mixed technical signals and high risk, requiring further confirmation before a trade. |
| May 27, 2026 | BUY | $13.68 | — / — | -6.2% | +23.9% | Positive clinical trial data for avexitide. |
| May 8, 2026 | BUY | $15.20 | — / — | -9.8% | -11.7% | Upcoming clinical trial catalysts for avexitide. |
| May 7, 2026 | HOLD | $16.06 | — / — | -8.7% | -12.4% | Upcoming Q3 2026 Phase 3 avexitide data readout. |
| May 4, 2026 | HOLD | $16.01 | — / — | -9.6% | -19.3% | Upcoming pivotal trial data for Avexitide. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.